Minocycline as adjunctive therapy for patients with unipolar psychotic depression: An open-label study

Miyaoka, Tsuyoshi; Wake, Rei; Furuya, Motohide; Liaury, Kristian; Ieda, Masa; Kimura, Kazunori; Tsuchie, Keiko; Taki, Michiyo; Ishihara, Kotomi; Araki, Toshimitsu; Horiguchi, Jun

doi:10.1016/j.pnpbp.2012.02.002

Cited by 195 publications

(125 citation statements)

References 37 publications

Supporting

Mentioning

120

Contrasting

Unclassified

Order By: Relevance

“…Minocycline was tested in an open-label trial as an adjunctive therapy for patients with unipolar psychotic depression and demonstrated efficacy in both depressive and psychotic symptoms [86]. NAC use has been more extensively explored in bipolar depression.…”

Section: The Future Of Research On Inflammation In Mddmentioning

confidence: 99%

Targeting the Inflammatory Pathway as a Therapeutic Tool for Major Depression

Noto¹,

Rizzo²,

Mansur³

et al. 2014

Neuroimmunomodulation

View full text Add to dashboard Cite

In the last decades convergent findings from several lines of evidence has revealed a robust association between major depressive disorder (MDD) and inflammatory pathways. Despite this, the translation of these findings into new and better treatments for MDD has not occurred. The objective of this study is to comprehensively review what is already known with reasonable certainty on inflammatory pathways in MDD, to clarify some points that have been insufficiently studied and to discuss the implications of these findings for future studies targeting inflammatory pathways as a therapeutic tool for individuals with MDD.

show abstract

Section: The Future Of Research On Inflammation In Mddmentioning

confidence: 99%

Targeting the Inflammatory Pathway as a Therapeutic Tool for Major Depression

Noto¹,

Rizzo²,

Mansur³

et al. 2014

Neuroimmunomodulation

View full text Add to dashboard Cite

show abstract

“…Antidepressant efficacy of minocycline, a second-generation antibiotic that also inhibits microglial activation, has been reported both clinically (Miyaoka et al, 2012) and in animal models (Henry et al, 2008, O'Connor et al, 2009, Arakawa et al, 2012, Hinwood et al, 2012. Furthermore, minocycline has been shown to be beneficial in pain states such as rheumatoid arthritis (Langevitz et al, 2000) and sciatica (Sumracki et al, 2012).…”

Section: Introductionmentioning

confidence: 99%

Minocycline modulates neuropathic pain behaviour and cortical M1–M2 microglial gene expression in a rat model of depression

Burke¹,

Kerr²,

Moriarty³

et al. 2014

Brain, Behavior, and Immunity

146

116

View full text Add to dashboard Cite

“…The tetracycline antibiotic minocycline may have antidepressant treatment effects [86]. Recent reviews emphasized aspirin because of a more favorable benefit to risk ratio and potentially better antidepressant effects compared with those of selective COX-2 inhibitors [87].…”

Section: Treat Inflammation In Depressionmentioning

confidence: 99%

Depression in the Context of Medical Disorders: New Pharmacological Pathways Revisited

Lang¹,

Walter²

2017

Neurosignals

View full text Add to dashboard Cite

The depressive state has been characterised as one of elevated inflammation, changed cardiovascular parameters and a deranged metabolic situation all of which holds promise for a better understanding and handling of treatment-resistance in affective disorders as well as for future developments in treatment algorithms. In this context several biomarkers are differentially regulated by antidepressant treatment and connected to metabolic, inflammatory, cardiovascular and apoptotic components of the pathophysiology, i.e. adiponectin, apolipoprotein-B, B-type natriuretic peptide, cortisol, CRP, cysteine, homocysteine, fibrinogen, adiponectin, BMI, glycated hemoglobin A1c, leptin, interferon-gamma, high-density lipoprotein, interleukin interleukin-1alpha, -1beta, -2, -4, -5, -6, -8, -10, -12, -13, -17, insulin-like growth factor-1, low-density lipoprotein, myeloperoxidase, osteoprotegerin, tumour necrosis factor alpha, troponins, triglycerides etc. In this context antidepressants exert different modulatory effects on the outcome, incidence and mortality concerning several severe disorders, i.e. cancer, diabetes, stroke, inflammation, stroke and cardiovascular risk. Vice versa different drugs used in the treatment of these disorders have a favourable effect in depressive states, e.g. statins, aspirine, NSAIDs, pioglitazone, celecoxib, peroxisome proliferator-activated receptor-gamma agonists and minocycline. In this review, actions of different antidepressant treatment strategies on cancer, stroke, diabetes and cardiovascular disorders are shown and the influence on the outcome of the disorders is differentially discussed. In conclusion a hypothetic model for the implication of actual findings in everyday clinical practice is proposed. In this context personalized treatment could be used to tailor treatment to specific individuals according to their clinical endophenotypes. Moreover a potential target for the development of novel intervention strategies might be used.

show abstract

Minocycline as adjunctive therapy for patients with unipolar psychotic depression: An open-label study

Cited by 195 publications

References 37 publications

Targeting the Inflammatory Pathway as a Therapeutic Tool for Major Depression

Targeting the Inflammatory Pathway as a Therapeutic Tool for Major Depression

Minocycline modulates neuropathic pain behaviour and cortical M1–M2 microglial gene expression in a rat model of depression

Depression in the Context of Medical Disorders: New Pharmacological Pathways Revisited

Contact Info

Product

Resources

About